See today's BioWorld Asia
To read the full story, subscribe or sign in.

Dong-A ST invests ₩25B in Ildong subsidiary, inks cancer deal

May 21, 2024
By Marian (YoonJee) Chu
To strengthen its cancer pipeline, South Korea’s Dong-A ST Co. Ltd. made a strategic investment of ₩25 billion (US$18.45 million) in Seocho-gu, Seoul-based Idience Co. Ltd., a cancer-focused subsidiary of Ildong Pharmaceutical Co. Ltd. on May 20.
BioWorld BioWorld Asia Deals and M&A Cancer Enzyme Asia-Pacific U.S.